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The Carba NP test has been evaluated to detect carbapenemase-producing Pseudomonas spp. 
directly from blood cultures. This rapid and cost-effective test permits an early identification 
of carbapenemase-producing Pseudomonas spp. directly from blood cultures with excellent 
sensitivity and specificity. Results may be useful in particular for guiding the first-line 











 Pseudomonas aeruginosa shows a remarkable capacity to resist antibiotics. This 
pathogen is intrinsically resistant to narrow-spectrum ß-lactams due to the constitutive 
expression of ß-lactamases, efflux pumps combined with low permeability of the outer-
membrane (1). In addition, acquired extended-spectrum β-lactamases (ESBLs) of the PER-, 
VEB-, and GES-types have been reported in P. aeruginosa (2). Consequently, the treatment 
of P. aeruginosa-related infections is becoming increasingly difficult and therefore 
carbapenem-containing treatments are frequently needed to treat those infections. 
Carbapenem resistance in Pseudomonas spp. can result from different mechanisms 
such as a decreased bacterial outer-membrane permeability (e.g. loss or modification of the 
OprD2 porin, or over-expression of efflux pumps), often associated with overexpression of ß-
lactamases possessing no significant carbapenemase activity (AmpCs) or to expression of true 
carbapenemases (1, 3). Carbapenemases have been reported in Pseudomonas spp. including 
the Ambler class A KPC- and GES-type ß-lactamases, and most commonly the Ambler class 
B or metallo-β-lactamases (MBLs) of the VIM-, IMP-, SPM-, GIM-, AIM-, DIM-, FIM and 
NDM-types (1, 3-7). 
Spread of carbapenemase-producing P. aeruginosa strains is a critical issue since 
those strains are resistant to almost all β-lactams. In addition, the early detection of 
carbapenemases is important because carbapenemase genes are usually located on 
transferable genetic determinant such as plasmids, leading to their rapid dissemination. 
Carbapenemase producers are commonly first screened based on susceptibility testing results. 
Then, specific phenotypical tests may be used to identify carbapenemase production in vitro, 
such as the modified Hodge test (8). Other detection methods based on the inhibitory 
properties of EDTA (against MBL), and boronic acid or clavulanic acid (for KPC), allow the 
discrimination of the different carbapenemase types. Since those techniques are performed on 











after the blood culture is flagged as positive and significant expertise is needed (9), 
particularly with P. aeruginosa (10). Molecular methods remain costly and require substantial 
expertise (11, 12). Overall, both phenotypic and molecular tests are time-consuming and 
consequently not suited for routine and rapid testings. One of the most recent and reliable 
technique for the detection of carbapenemase-producing P. aeruginosa is the biochemically-
based Carba NP test (11). This test applied on isolated cultures detects all types of 
carbapenemase-producing P. aeruginosa isolates with the exception of several GES-type 
producers (13). In addition, this test may be used for detecting carbapenemase-producing 
Enterobacteriaceae from blood (12). 
 The aim of this study was to determine the ability of the Carba NP test to detect 
carbapenemase-producing Pseudomonas species directly from blood cultures. Since the 
successful treatment of bacteremia depends on prompt administration of the appropriate 
antibiotherapy, the routinely use of the Carba NP test directly on blood culture may guide the 
first-line therapy for patients with sepsis (13). 
The Carba NP test was performed on spiked blood cultures from which the positivity 
was assessed using the BactAlert blood culture system (bioMérieux, Marcy l’Etoile, France). 
Blood cultures (10 ml of sterile human blood) were inoculated with 1 x 103 CFU of each 
strain (500 μl total volume) (Table 1). The 1 x 103 inoculum was prepared by diluting 0.5 
McFarland suspension, (108 CFU/ml) in sterile water. Then, aerobic bottles (BacT/ALERT 
SA Standard Aerobic bottles without charcoal) were incubated until a positivity of the blood 
culture was detected by the BactAlert system (detection time ranged from 6 to 15 h). As 
previously described, the final bacterial count at time of positivity ranged from 5 x 107 to 5 x 
109 CFU/ml (14). 
 The Carba NP test from blood cultures adapted from the previously published 











with 70 μg/ml ZnSO4 (final concentration) without imipenem were inoculated with five drops 
(75 μl) of the positive blood culture in two Eppendorf tubes (tube A and B). Inoculated BHI 
were then incubated under agitation at 37°C for 3 h. Bacteria were recovered by 
centrifugation at 10,000 x g for 5 min. This optimized protocol of the Carba NP test was 
directly performed on this bacterial pellet (15). Briefly, the bacterial pellet was resuspended in 
100 μl of a Tris-HCl 20 mM lysis buffer (B-PER II, Bacterial Protein Extraction Reagent, 
Pierce, Thermo Scientific, Villebon-sur-Yvette, France) and vortexed for 1 min. The 
enzymatic bacterial suspension, was mixed with 100 μl of a diluted phenol red solution 
containing 0.1 mM ZnSO4 (Merck Millipore, Guyancourt, France) in the first tube (A) and 
with a diluted phenol red solution containing 0,1 mM ZnSO4 and supplemented with 6 mg/ml 
imipenem monohydrate (Sigma, Saint-Quentin-Fallavier, France) in the second tube (B). 
Mixture of the phenol red (± imipenem) solutions and the enzymatic suspension being tested 
were incubated at 37°C for a maximum of 2 h. Results of the Carba NP test were interpreted 
as follows: (i) both tubes A and B red; non carbapenemase-producing isolate, (ii) tube A red 
and tube B yellow/orange; carbapenemase-producing isolate, and (iii) tube A yellow/orange 
and tube B yellow/orange; not interpretable result. All experiments were performed in 
triplicate and test results were interpreted by technicians who were blinded to the identity of 
the samples. 
A panel of forty-two carbapenemase-producing Pseudomonas species was included in 
the study (Table 1) and seventy-two non-carbapenemase producers Pseudomonas were used 
as controls (Table 2). All the strains had previously been characterized for their β-lactamase 
content and carbapenemase resistance mechanisms at the molecular level in previous works 
(11). 
This optimized protocol of Carba NP test (15), performed directly from spiked blood 











with non-carbapenemase-mediated mechanisms, such as those combining outer-membrane 
permeability defects +/- associated with overproduction of cephalosporinase and/or ESBLs. 
The sensitivity and specificity of the test were 100% under those conditions. Noteworthy, 
GES-type producers were well detected from blood cultures whereas they were not from 
isolated colonies (11). This difference might be explained by i) the increased inoculum 
recovered during experiments blood cultures, as previously observed for ESBL-producing 
Enterobacteriaceae (14), and ii) increased ß-lactamase production in liquid medium. 
Furthermore, the test was positive for two strains (IMP-1-producing Pseudomonas stutzeri 
PB207 and Pseudomonas putida NTU 92/99) that were susceptible to carbapenems (MIC  2 
g/ml (16). 
The Carba NP test combines multiple advantages. It is inexpensive, rapid, 
reproductible, highly sensitive and specific. Use of this test would be helpful for choosing a 
first-line therapy based on an aminoglycoside associated with a fluoroquinolone rather than ß-
lactam-containing combinations in case of positivity, in particular when treating pneumonia. 
It can also be useful for detecting carbapenemase-producers in an attempt to control outbreaks 
and to rapidly differentiate between carbapenemase producers (transferable resistance 
determinant) and non-carbapenemase producers (non-transferable resistance determinant). 
Actually, by preventing their spread, and therefore statistically reducing their genetic 
exchanges with other bacterial species, an early identification of carbapenemase-producing P. 
aeruginosa may prevent further dissemination of carbapenemases to Enterobacteriaceae. It 
corresponds, to the best of our knowledge, to the first easy-to-handle technique allowing rapid 
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Table 1. Carbapenemase-producing strains included in this study and found positive using the Carba NP test
 
Ambler class Carbapenemase type Organism Carbapenemase
MIC (μg/mL) 
IMP MER 
A KPC P. aeruginosa COL KPC-2 >32 >32 
  P. aeruginosa P13 KPC-2 >32 >32 
  P. aeruginosa PA-2 KPC-2 >32 >32 
  P. aeruginosa PA-3 KPC-2 >32 >32 
 GES P. aeruginosa GW-1 GES-2 3 1 
  P. aeruginosa P-35 GES-5 >32 >32 
B VIM P. aeruginosa P0510 VIM-1 >32 >32 
  P. fluorescens COU VIM-1 >32 >32 
  P. aeruginosa JOU VIM-1 >32 >32 
  P. aeruginosa ABA VIM-1 >32 >32 
  P. aeruginosa REZ VIM-2 >32 >32 
  P. putida 9335 VIM-2 >32 >32 
  P. stutzeri P511503100 VIM-2 >32 >32 
  P. aeruginosa BY25753 VIM-2 >32 >32 
  P. aeruginosa V919005 VIM-2 >32 >32 
  P. aeruginosa AK5493 VIM-2 >32 >32 
  P. aeruginosa KA-209 VIM-2 >32 >32 
  P. putida NTU 91/99 VIM-2 >32 >32 
  P.aeruginosa COL-1 VIM-2 >32 >32 
  P. aeruginosa CAS VIM-2 >32 >32 
  P. aeruginosa JAC VIM-4 >32 >32 
   P. aeruginosa MED VIM-5 >32 >32 
 IMP P. aeruginosa 12870 IMP-1 12 >32 
  P. stutzeri PB207 IMP-1 2 4 
  P. putida NTU 92/99 IMP-1 1 0.19 
  P. aeruginosa IMP-1 >32 >32 
  P. aeruginosa MKA IMP-1 16 >32 
  P. aeruginosa 0607097 IMP-2 >32 >32 
  P. aeruginosa ITA IMP-13 >32 >32 
  P. aeruginosa PADI IMP-13 4 3 
   P. aeruginosa TSE IMP-13 >32 >32 
 NDM P. aeruginosa 453 NDM-1 >32 >32 
   P. aeruginosa 353 NDM-1 >32 >32 
 GIM P. aeruginosa 73-15574 GIM-1 >32 >32 
  P. aeruginosa 73-15553A GIM-1 >32 >32 
   P. aeruginosa 73-5674 GIM-1 >32 >32 
 AIM P. aeruginosa WCH2677 AIM-1 >32 >32 
  P. aeruginosa WCH2813 AIM-1 >32 >32 
   P. aeruginosa WCH2837 AIM-1 >32 >32 
 SPM P. aeruginosa 16 SPM-1 >32 >32 
 DIM P. stutzeri 13 DIM-1 >32 >32 
 FIM P. aeruginosa FIM-1 >32 >32 













Table 2. Lack of detection of carbapenemase activity using the Carba NP test 
 
Resistance mechanism Organism Resistance determinant(s) MIC (μg/ml) IMP MER 
Wild type P. aeruginosa 76110 Reference strain     0.75   0.19 
 P. aeruginosa PU21 Reference strain     1.5   0.75 
 P. aeruginosa ATCC 27853 Reference strain     2   0.25 
 P. aeruginosa PA01 Reference strain     1   0.5 
 P. putida CIP 55-5 Reference strain     0.5   3 
AmpC overproducer P. aeruginosa 3-12  overexpression of chromosomal AmpC     3   0.25 
 P. aeruginosa Ved overexpression of chromosomal AmpC     0.12   0.19 
Overproduced efflux P. aeruginosa PA01 Mex C/D-OprJ >32  4
 P. aeruginosa PT629 Mex A/B-OprM     1.5   1.5 
 P. aeruginosa PA01 Mex X/Y-OprM     1.5   0.75 
Porin deficiency P. aeruginosa PA01 OprM deficient     0.75   0.5 
 P. aeruginosa H729 OprD deficient >32   6 
 P. aeruginosa Paeȕ-02 OprD deficient     4   4 
 P. aeruginosa Paeȕ-05 OprD deficient   16   8 
 P. aeruginosa Paeȕ-30 OprD deficient     8   8 
 P. aeruginosa Paeȕ-31 OprD deficient   16   8 
Porin deficiency + 
overproduced efflux P. aeruginosa Paeȕ-19 OprD deficient + MexA/B-OprM     4   4 
 P. aeruginosa Paeȕ-29 OprD deficient + MexA/B-OprM + MexX/Y-OprM   16 32 
 P. aeruginosa Paeȕ-01 OprD deficient + MexX/Y-OprM + MexC/D-OprJ     4   8 
Porin deficiency + AmpC 
over-production 
P. aeruginosa Paeȕ-03 OprD deficient + AmpC   16   8 
P. aeruginosa Paeȕ-12 OprD deficient + AmpC  16  8
 P. aeruginosa Paeȕ-13 OprD deficient + AmpC   16   8 
 P. aeruginosa Paeȕ-14 OprD deficient + AmpC   16   4 
 P. aeruginosa Paeȕ-16 OprD deficient + AmpC   32   4 
 P. aeruginosa Paeȕ-23 OprD deficient + AmpC   32 16 
 P. aeruginosa Paeȕ-25 OprD deficient + AmpC     8   8 
 P. aeruginosa Paeȕ-26 OprD deficient + AmpC     4   4 
 P. aeruginosa Paeȕ-32 OprD deficient + AmpC   64 16 
Porin deficiency + 
overproduced AmpC + 
overproduced efflux 
P. aeruginosa Paeȕ-04 OprD deficient + AmpC + MexA/B-OprM   16 16 
P. aeruginosa Paeȕ-24 OprD deficient + AmpC + MexA/B-OprM   32 32 
 P. aeruginosa Paeȕ-28 OprD deficient + AmpC + MexA/B-OprM   16   4 











 P. aeruginosa Paeȕ-21 OprD deficient + AmpC + MexX/Y-OprM 16 32 
 P. aeruginosa Paeȕ-22 OprD deficient + AmpC + MexC/D-OprJ 8 4 
 P. aeruginosa Paeȕ-06 OprD deficient + AmpC + MexX/Y-OprM + MexC/D-OprJ 16 8 
 P. aeruginosa Paeȕ-07 OprD deficient + AmpC + MexX/Y-OprM + MexC/D-OprJ 16 8
 P. aeruginosa Paeȕ-08 OprD deficient + AmpC + MexX/Y-OprM + MexC/D-OprJ 16 8 
 P. aeruginosa Paeȕ-09 OprD deficient + AmpC + MexX/Y-OprM + MexC/D-OprJ 16 8 
 P. aeruginosa Paeȕ-11 OprD deficient + AmpC + MexX/Y-OprM + MexC/D-OprJ 16 8 
 P. aeruginosa Paeȕ-17 OprD deficient + AmpC + MexX/Y-OprM + MexC/D-OprJ 32 8 
 P. aeruginosa Paeȕ-18 OprD deficient + AmpC + MexA/B-OprM + MexX/Y-OprM 64 64 
 P. aeruginosa Paeȕ-27 OprD deficient + AmpC + MexA/B-OprM + MexX/Y-OprM 32 64
 P. aeruginosa Paeȕ-10 OprD deficient + AmpC + MexA/B-OprM + MexC/D-OprJ 16 8 
 P. aeruginosa Paeȕ-20 OprD deficient + AmpC + MexA/B-OprM + MexC/D-OprJ 16 8 
ESBL P. aeruginosa GES-1 1 0.75
 P. aeruginosa DEJ GES-9 2 1 
 P. aeruginosa RNL-1 PER-1 6 6 
 P. aeruginosa PER-1 13 3 
 P. aeruginosa PER-1 1.5 0.38 
 P. aeruginosa PER-1 6 1 
 P. aeruginosa PER-1 3 1.5 
 P. aeruginosa PER-1 >32 12 
 P. aeruginosa PER-1 12 3 
 P. aeruginosa PER-1 >32 12 
 P. aeruginosa PER-1 0.25 0.016 
 P. aeruginosa PER-1 >32 8 
 P. aeruginosa PER-1 >32 >32 
 P. aeruginosa 15 VEB-1 2 1.5 
 P. aeruginosa 51170 BEL-1 1 0.5 
 P. aeruginosa SHV2a 1.5 3 
 P. aeruginosa 1782 SHV-5 2 2 
 P. aeruginosa SHAM TEM-4 3 0.75 
 P. aeruginosa PU21 OXA-2 2 1 
 P. aeruginosa PAO38 OXA-4 0.016 0.19 
 P. aeruginosa PU 21 OXA-10 2 1.5 
 P. aeruginosa PU 21 OXA-11 3 1.5 
 P. aeruginosa NAJ OXA-13 2 1.5 
 P. aeruginosa PU 21 OXA-14 2 2 
 P. aeruginosa MUS OXA-18 + OXA-20 >32 >32 
 P. aeruginosa ED OXA-28 2 0.75 











 P. aeruginosa PG13 OXA-32 >32 12 
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